Cytosar Injection
Cytarabine
20mg/ml
Pharmacia N.V/S.A.
| Pack size | 1 Vial + 1 Solvent Ampoule (5ml) |
|---|---|
| Dispensing mode | POM |
| Source | BELGIUM |
| Agent | Modern Pharmaceutical Co. |
| Retail Price | 17.50 AED |
Indications
Cytosar Injection is used for:
Acute myeloid leukaemia, acute lymphocytic leukaemia (ALL), lymphomas, Leukaemic meningitis
Adult Dose
Acute Nonlymphocytic Leukemia
IV administration for remission induction
100-200 mg/sq.meter/day for 5-10 days; begin second course in 2-4 weeks after initial therapy if necessary OR
100 mg/sq.meter for 7 days OR
100 mg/sq.meter/dose q12hr for 7 days
Intrathecal (IT) administration for remission induction
5-75 mg/sq.meter q2-7Days until CNS findings normalize
IV administration for remission maintenance
70-200 mg/sq.meter/day for 2-5 days at monthly intervals
IM administration for remission maintenance
1-1.5 mg/kg single dose for maintenance at 1- 4 week intervals
Meningeal Leukemia
IT administration
30 mg/sq.meter intrathecal (IT) q4Days until CSF findings normal plus one additional dose
Refractory Leukemia
IV administration
3 g/sq.meter IV (infusion over 1-3 hours) q12hr x 4-12 doses
Repeat q2-3Weeks
Child Dose
Renal Dose
Administration
IV Administration
Rapid IV, infusion over 1-3 hr, or SC intrathecal
Has been administered by IM & continuous SC infusion
IT: Patient should lie flat for 1 hour after lumbar puncture
Liposomal: To reduce incidence of arachnoiditis, administer dexamethasone concurrently
IV Preparation
Reconstitute vials in BWI containing benzyl alcohol 0.945% as follows (CAUTION: Do not use benzyl alcohol for intrathecal inj)
100 mg vial: add 5 mL diluent to 20 mg/mL
500 mg vial: add 10 mL diluent to 50 mg/mL
1 g vial: add 10 mL diluent to 100 mg/mL
2 g vial: add 20 mL diluent to 100 mg/mL
Contra Indications
Hypersensitivity; pregnancy and lactation.
Precautions
Hepatic and renal dysfunction, severe infections, preexisting drug-induced bone marrow suppression. Monitor WBC, platelet counts and blood uric acid frequently. Assess renal and hepatic function periodically.
Lactation: not known if excreted in breast milk, avoid
Pregnancy-Lactation
Pregnancy Category: D
Lactation: not known if excreted in breast milk, avoid
Interactions
May reduce efficacy of gentamicin, digoxin and flucytosine.
Potentially Fatal: Potentiates bone marrow depression with radiotherapy and other myelotoxic drugs.
Adverse Effects
Side effects of Cytarabine :
1-10%
Anorexia, Nausea, Vomiting, Diarrhea, Oral/anal inflammation, Thrombophlebitis, Bleeding, Myelosuppression, Rash, Fever, Hepatic dysfunction
Frequency Not Defined
Headache, Neuropathy, Chest pain, Pericarditis, Pneumonia, Anemia, Bleeding, Leukopenia, Thrombocytopenia, Kidney disease, Infectious disease, Sepsis, "Cytarabine syndrome": fever, myalgia, bone pain, rash, conjunctivitis, malaise, Skin ulcers, Cellulitis, Urinary retention, Neuritis, Jaundice, Anaphylaxis
Potentially Fatal: Convulsions. Cerebellar dysfunction, respiratory distress syndrome, GI perforation, bone marrow suppression.
Mechanism of Action
Cytarabine acts by interfering with DNA synthesis specifically at the S-phase of the cell cycle. It is a potent myelosuppressant and requires careful haematological monitoring during its use. It also has antiviral property.
Note
Cytosar 20mg/ml Injection manufactured by Pharmacia N.V/S.A.. Its generic name is Cytarabine. Cytosar is availble in United Arab Emirates.
Farmaco UAE drug index information on Cytosar Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.